Baptist Health Cancer Care | Association Partnerships

Noah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.

In an interview with Targeted Oncology, Hina Saeed, MD, discussed how AI and radiomics are changing the landscape of radiation oncology.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

Rohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.

Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

In an interview with Targeted Oncology, Manmeet Ahluwalia, MD, MBA, FASCO, discussed the Cancer Moonshot program, its progress, and the next steps.

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

In an interview with Targeted Oncology, Manmeet S. Ahluwalia, MD, provided insights into his personal career and goals and the transformative potential of oncology.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.

Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.

In an interview with Targeted Oncology, Eric Schroeder, MD, discussed the transformative shift that the landscape of ovarian cancer treatment has undergone in recent years.

In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.

Federico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.

In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.

In an interview with Targeted Oncology, Michael Zinner, MD, explored the scientific challenges and breakthroughs shaping the landscape of oncology care in the context of World Cancer Day.

Federico Albrecht, MD, discusses Miami Cancer Institute's specific protocol for hospitalized patients with small cell lung cancer.

In an interview with Targeted Oncology, Guenther Koehne, MD, discussed the latest research surrounding autologous and allogeneic stem cell transplants.